POEMS syndrome with multiple ganglioside/paraneoplastic antibodies misdiagnosed as CIDP: a case report - Top-Institutions - MDSpire

POEMS syndrome with multiple ganglioside/paraneoplastic antibodies misdiagnosed as CIDP: a case report

  • By

  • Mengmeng Fan

  • Jiaxiu He

  • Shihui Sun

  • Linyuan He

  • Zhao Zhong

  • April 30, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Hematology
    • Immunology

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Hematology
    • Neuroimmunology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology
    • Hematology
    • Oncology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Hematology
    • Neuro-oncology

Original Source(s)

POEMS syndrome with multiple ganglioside/paraneoplastic antibodies misdiagnosed as CIDP: a case report

  • by Mengmeng Fan, Jiaxiu He, Shihui Sun, Linyuan He, Zhao Zhong

  • April 30, 2026

Related Content

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

Lymphoma risk in autoimmune diseases with multiple medication use: analysis from the LIFE Study

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.